For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250226:nRSZ4446Ya&default-theme=true
RNS Number : 4446Y Genus PLC 26 February 2025
For Immediate Release
26 February 2025
Genus plc
('Genus', or the 'Company')
Non-Executive Director Retirement
Genus (LSE: GNS), a leading global animal genetics company, announces that
Professor Jason Chin has informed the Company of his intention to step down
from the Genus Board, effective from the end of May 2025, as he will be taking
on a significant new role as Founding Director of the Generative Biology
Institute at the Ellison Institute of Technology. Professor Chin has served
as a Non-Executive Director, Chairman of the Company's Scientific Advisory
Board and advisor to the Company's Global Portfolio Steering Committee for
four years. Upon stepping down from the Board, Professor Chin will remain a
member of the Scientific Advisory Board.
The Board has initiated a comprehensive search for Professor Chin's successor
and will provide an update once this process has concluded.
Commenting on the changes, Iain Ferguson, Chairman of Genus, said:
"Over the last four years Professor Jason Chin has provided the Company with
significant scientific expertise, guidance and insight as we progress our
innovative science platforms. We wish him well in his new role."
Genus Tel: +44(0)1256 345970
Iain Ferguson, Chairman
Jorgen Kokke, Chief Executive
Burson Buchanan Tel: +44(0)207 466 5000
Charles Ryland; Toto Berger; Sophie Wills; Verity Parker
This announcement is available on the Genus website www.genusplc.com
(http://www.genusplc.com/)
About Genus
Genus is a world-leading animal genetics company. Genus creates advances to
animal breeding and genetic improvement by applying biotechnology and sells
added value products for livestock farming and food producers. Its technology
is applicable across livestock species and is currently commercialised by
Genus in the dairy, beef and pork food production sectors.
Genus's worldwide sales are made in over seventy-five countries under the
trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen,
embryos and breeding animals with superior genetics to those animals currently
in farms. Genus's customers' animals produce offspring with greater production
efficiency, and quality, and use these to supply the global dairy and meat
supply chains.
The Group's competitive edge has been created from the ownership and control
of proprietary lines of breeding animals, the biotechnology used to improve
them and its global supply chain, technical service and sales and distribution
network.
With headquarters in Basingstoke, United Kingdom, Genus companies operate in
over twenty-five countries on six continents, with research laboratories
located in Madison, Wisconsin, USA.
Regulatory Notes
This announcement is made in accordance with Listing Rule 6.4.6R. The person
responsible for making this announcement on behalf of the Group is Vaughn
Walton (Interim Company Secretary).
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BOAPPUPUPUPAGBA